Anzeige
Mehr »
Mittwoch, 14.01.2026 - Börsentäglich über 12.000 News
Gold auf Rekordhoch: Eine der spannendsten Gold-Stories 2026 steht ganz am Anfang
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41MHW | ISIN: CA8629461002 | Ticker-Symbol: MIG3
Frankfurt
13.01.26 | 15:25
6,600 Euro
+3,94 % +0,250
1-Jahres-Chart
STRATEGY INC CDR Chart 1 Jahr
5-Tage-Chart
STRATEGY INC CDR 5-Tage-Chart

Aktuelle News zur STRATEGY INC CDR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiAres Raises Over $7 Billion For Credit Secondaries Strategy, Doubling Target1
STRATEGY INC CDR Aktie jetzt für 0€ handeln
DiStout Acquires Pointe Advisory And Launches Stout Strategy Practice1
DiPraxis Precision Medicines, Inc.: Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy3
DiAmerica's Car-Mart, Inc.: America's Car-Mart Advances SG&A Cost Control Strategy With Phase 2 Store Consolidations1
DiCimpress plc: Cimpress Accelerates Strategy for Elevated Product Growth205- National Pen and BuildASign to further fuel VistaPrint's product expansion; Company announces leadership transition at National Pen - Cimpress plc (Nasdaq: CMPR) today announced the next step...
► Artikel lesen
DiAbend-Update: Kurs-Explosion bei Microstrategy? Diese Bewegung hat einen Grund
DiSEMCO Technologies Achieves Several Key Milestones in Executing Its Growth Strategy182Opening of a subsidiary in China to strengthen the Group's commercial and industrial presence in one of its strategic markets Acceleration of industrial ramp-up through automation of the...
► Artikel lesen
DiStrategy macht größten Bitcoin (BTC)-Kauf seit Juli 202543
DiMar Vista's U.S. Quality Strategy Divested Its Stake in Equifax (EFX)2
DiIs Alibaba's Cash Flow Pressure Making Its Growth Strategy Riskier?15
DiDoes Grid Reliability Pose a Threat to Hut 8's Power Strategy?9
DiAres Raises Over $7 Billion For Leading Credit Secondaries Strategy1
DiAeris Receives Frost & Sullivan's 2025 Global Competitive Strategy Leadership Recognition for Advancing Next-Generation IoT Connectivity Management262Delivering global market leadership through IoT connectivity innovation, ecosystem scale, and customer-centric executionSAN ANTONIO, Jan. 13, 2026 /PRNewswire/ -- Frost & Sullivan is pleased...
► Artikel lesen
DiEnterprise Strategy Group Economic Validation Finds Starburst Delivers 45% Lower Total Cost of Ownership and 414% ROI122Independent analysis shows reduced operational costs, accelerated AI initiatives, and significant performance gainsBOSTON, Jan. 13, 2026 /PRNewswire/ -- Starburst, the data platform for apps...
► Artikel lesen
DiDIAGNOS Inc.: DIAGNOS Advances Regulatory Strategy for CARA in Key Markets: Updates on Health Canada, FDA, and SFDA Progress4
DiLPL Financial Names Ilan Davidovici As EVP Of Corporate Strategy1
DiDeFi Development Corporation: DeFi Development Corp. Adopts Solstice YieldVault to Power Onchain Treasury Yield Strategy6
DiStrategy-Aktie: Es sieht nicht rosig aus466Die Strategy Holding hat erneut beim Bitcoin zugegriffen, doch die Probleme des Unternehmens sind unverändert groß. Besonders der mNAV sorgt bei Anlegern für Sorgenfalten. Neue Käufe Die Strategy-Holding...
► Artikel lesen
DiTTE Strategy expands into the Gulf Region and opens office in Dubai125HAMBURG, Germany and DUBAI, UAE, Jan. 13, 2026 /PRNewswire/ -- TTE Strategy has opened its first office outside Europe in Dubai, expanding its footprint into the Gulf Region. With this step...
► Artikel lesen
DiKymera Therapeutics, Inc.: Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs41KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027 KT-579 Phase 1 HV clinical trial expected...
► Artikel lesen
Weiter >>
2.677 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1